ENSG

As of 2026-10-26, ENSG scores 49out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. ENSG trades at $176.92, within its fair-value band.

ENSG scores 49 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 49. Its strongest factor is value at 65 (strong), where it screens cheap on the model's valuation inputs, followed by quality at 53. The weakest is momentum at 36, where price trend is the soft spot. Among Healthcare stocks it sits in the lower 44% of Healthcare names by composite.

On valuation, ENSG is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 50. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on ENSG, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where ENSG sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for ENSG runs $137.53–$180.74. Current price $176.92 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.